This update covers the latest health sector developments, including Moderna's COVID-19 vaccine review, GSK's asthma drug FDA ...

Trump administration to restrict COVID vaccines to seniors and high-risk groups, pending more data for everyone else.

Moderna, Inc. (NASDAQ:MRNA) announced on Friday that it has submitted a marketing application to the U.S. Food and Drug ...

Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the SARS-CoV-2 ...

An FDA committee on Thursday recommended that COVID-19 vaccines for the 2025-2026 respiratory virus season — which, for the ...

In a major and controversial policy shift, the FDA announced in a New England Journal of Medicine article that updated ...

Despite the fact that vaccines against COVID have already undergone strict safety reviews and that people continue to die ...

On May 22, an FDA advisory committee unanimously recommended COVID-19 vaccine manufacturers target the JN.1 variant in their formulations.  The Vaccines and Related Biological Products Advisory ...

The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

The vaccine is expected to remain available for anyone who is at least 65 or who has a medical condition, leaving many ...

The FDA is implementing stricter guidance for the approval of COVID-19 vaccines, according to a paper published in The New England Journal of Medicine.

The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines.